Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SR-8541A in Advanced/Metastatic Solid Tumors
NCT06063681Phase 1Recruiting
- Sponsor
- Stingray Therapeutics
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vizenpistat in solid tumor (2 arms), sponsored by Stingray Therapeutics. Primary endpoints: Frequency and severity of Adverse Events and Recommended Phase 2 Dose of SR-8541A at 28 days. Started Oct 2023; status: recruiting.
02
Drugs
vizenpistat
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06063681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06063681.